CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)

被引:44
作者
Hancock, GE [1 ]
Heers, KM [1 ]
Smith, JD [1 ]
Scheuer, CA [1 ]
Ibraghimov, AR [1 ]
Pryharski, KS [1 ]
机构
[1] Wyeth Lederle Vaccines, Dept Immunol Res, W Henrietta, NY 14586 USA
关键词
eosinophils; fusion (F) protein; oligodeoxynucleotides (ODN); unmethylated CpG; respiratory syncytial virus (RSV); type 1 T cells; subunit vaccines;
D O I
10.1016/S0264-410X(01)00228-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The feasibility of using oligodeoxynucleotides (ODN) containing unmethylated CpG motifs as parenteral adjuvants for subunit vaccines against RSV was tested in BALB/c mice. Compared with immunization with natural F protein adsorbed to aluminum hydroxide (F/AlOH) adjuvant alone, coadministration of F/AlOH with CpG ODN resulted in statistically significant increases in serum neutralization titers, an enhanced generation of splenic antigen-dependent killer cell precursors, and accelerated clearance of infectious virus from lungs 4 days after challenge. The statistically significant increases in serum IFN gamma and anti-F protein IgG2a titers, and significantly diminished pulmonary IL-5 and eosinophilia after challenge indicated that CpG ODN enhanced the ability of F/AlOH to elicit type 1 immune responses. F protein-specific serum IgE titers were also reduced. Further analysis of pulmonary inflammatory cells demonstrated an expansion of CD8(+) T cells, relative to the CD4(+) T cell compartment. The potency of CpG ODN was not adversely affected in gene knockout mice devoid of the p35 chain of the IL-12 heterodimer. Taken together, the results suggest a novel formulation for naive recipients of F protein-based subunit vaccines that does not result in a type 2 phenotype. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:4874 / 4882
页数:9
相关论文
共 41 条
[41]   Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12-and IFN-γ-dependent mechanisms [J].
Walker, PS ;
Scharton-Kersten, T ;
Krieg, AM ;
Love-Homan, L ;
Rowton, ED ;
Udey, MC ;
Vogel, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6970-6975